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ABSTRACT
Recent studies have reported that lymphocytes pro-
duce, transport and bind dopamine present in
plasma. However, the action of dopamine on HIV-1
gene expression in cells of the immune system has
not yet been examined. Here, we have investigated
the regulation of HIV-1 expression by dopamine in
Jurkat T cells and in primary blood mononuclear
cells (PBMC). HIV-1 replication was increased by
dopamine, which correlated with the increased levels
of HIV-1 transactivation. Our transient expression
data revealed that dopamine stimulated transcription
through the NF-κB element present in the long terminal
repeat. The importance of NF-κB sites was confirmed
by using vectors containing wild-type or mutant κB
sites in a heterologous promoter. Consistent with the
role of NF-κB in mediating dopamine responsiveness,
the proteasome inhibitor MG132 abolished dopamine-
induced transcriptional activation. We further
explored the effect of dopamine in the presence of
phorbol esters or tumor necrosis factor-α (TNF-α)
known to activate NF-κB. The combination of
dopamine and TNF-α led to a stimulation of HIV-1
transcription and replication. However, in contrast
with TNF-α, dopamine treatment did not affect NF-κB
DNA binding activity nor the concentrations of p50,
p65 and IκB-α proteins, which suggests a distinct NF-κB
activation mechanism. These results reveal a new
link between the dopamine system, cytokine signaling
pathway and regulation of gene expression via the
involvement of NF-κB in T cells and PBMC.
INTRODUCTION
Knowledge of the molecular mechanisms which govern
expression of the human immunodeficiency virus type 1 (HIV-1)
genome is essential to understand the persistent viral replication
and viral latency underlying HIV-1-associated pathogenesis.
HIV-1 transcription is directed by the long terminal repeat
(LTR) through interactions with a number of viral and host cell
proteins, such as the transcription factors Sp1 and NF-κB
(reviewed in 1,2). Viral production can be induced in response
to a variety of agents which mediate their action through different
transcription factors. Interleukin 6 affects viral expression
through the transcription factor NF-IL6 (3). A number of stimuli,
such as tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1)
(4), reactive oxygen intermediates (5), phosphatidylcholine
hydrolysis (6), transforming growth factor-β (TGF-β) (7) and
amino acid analogs (8) stimulate HIV-1 transcription by
activation of the NF-κB transcription factor family (9–11).
Upon stimulation-induced nuclear translocation, NF-κB pro-
teins activate HIV-1 gene transcription through binding to the
κB enhancer motif located in the –109/–79 LTR region.
We have reported recently that the neuromodulator
dopamine is involved in the regulation of HIV-1 gene expression
in neuronal cells, via the transcription factor COUP-TF, acting
on the proximal –68/+80 LTR region (12). The dopamine system
is involved in the control of motor, cognitive and neuroendocrine
processes in the central nervous system. Dopamine mediates its
effects by activating second messengers through its interaction
with G-protein-coupled dopamine receptors. The action of
dopamine on target cells affects multiple intracellular pathways,
such as formation of cyclic AMP, inositolphosphates and
arachidonic acid, and modulates cellular electrical activity by
altering the properties of ion channels (13–15). Pathways to the
nucleus may involve adenyl cyclase and protein kinase A
(PKA) or Ca2+, protein kinase C (PKC) or tyrosine kinase proteins,
which regulate the activity of a number of transcription factors,
such as CREB, AP-1 and COUP-TF through transcriptional
and post-transcriptional events. In addition to cell surface
receptor binding, dopamine is also transported in cells via
specific uptake mechanisms (reviewed in 16).
Recent studies have established that lymphocytes are also
able to actively produce and transport catecholamines, such as
dopamine (17,18). Dopamine is able to modulate peripheral
blood lymphocyte activity via dopamine D3 and D5 receptors
(19,20). However, effects of dopamine on HIV-1 expression in
cells of the immune system have not been examined.
In this study, we have investigated the regulation of HIV-1
expression by the neuromodulator dopamine in T lymphocytes
and in human primary peripheral blood mononuclear cells*To whom correspondence should be addressed. Tel: +33 388 45 67 18; Fax: +33 388 60 08 06; Email: schaeffer@neurochem.u-strasbg.fr
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(PBMC). Our findings reveal that dopamine is able to stimulate
viral replication in Jurkat T cells and in PBMC. This correlates
with increased transcription from the HIV-1 LTR through the
NF-κB element. Moreover, we have examined the effect of
dopamine in the presence of phorbol esters and TNF-α.
Finally, our results indicate that the mechanism of dopamine-
mediated stimulation is distinct from the classic NF-κB activation
mechanism involving signal-induced NF-κB nuclear translocation,
and presents similarities with the recently reported TGF-β-
mediated HIV-1 activation (7).
MATERIALS AND METHODS
Materials
Cell culture media and all reagents, unless specified, were
obtained from Sigma. [14C]chloramphenicol was obtained
from NEN Life Science.
Plasmid constructs
The LTR(LAI)-CAT and LTR(HXB2)-Luc vectors were
described previously (12,21). LTR(HXB2)∆GC-CAT, LTR(HX-
B2)∆κB-CAT, LTR(HXB2)∆κB/GC-CAT were described
previously (22). The –283/+80LTR∆κB/GC-CAT vector was
constructed by isolating the EarI–HindIII LTR insert from
LTR(HXB2)∆κB/GC-CAT and subcloning the blunt-ended
fragment into the SmaI site of pUC19-CAT0. The GC-WAP-
CAT, GCmut-WAP-CAT, κB-WAP-CAT, κBmut-WAP-CAT
vectors contain respectively the wild-type and mutant (–79/–45)
GC-rich or (–104/–79) NF-κB region from HIV-1 LTR (23).
Cell culture, isolation and propagation of PBMC
Jurkat T cells were grown in RPMI 1640 supplemented with
10% fetal calf serum, 10 mM HEPES and penicillin/strepto-
mycin (100 U/ml). Human PBMC were separated from whole
blood collected from HIV seronegative donors by Ficoll-Paque
(Pharmacia, Uppsala, Sweden) density gradient centrifugation,
washed thoroughly to remove contaminating platelets and
cryopreserved. Cells were cultured in RPMI 1640 supplemented
with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine,
100 U of penicillin/ml and 100 µg of streptomycin/ml. Cells
were activated with 2 µg/ml phytohemaglutinin and 20 U/ml
interleukin-2 for 2–3 days before HIV infection.
Transfections, CAT and luciferase assays
Cells (5 × 106) were transfected by the DEAE-dextran method
with 1 pmol of reporter plasmid and 0.5 pmol of expression
vector. When indicated, cells were treated 1 day after transfection
with dopamine (100 µM), phorbol myristate acetate (PMA,
10 ng/ml), TNF-α (10 ng/ml; Genzyme), MG132 (10 µM) or
cyclosporine A (0.5–5 µg/ml; Sandoz) and incubated for
another 24 h before harvesting. Each transfection was repeated
at least four times with different plasmid preparations. Chloram-
phenicol acetyltransferase (CAT) assays were performed as
described previously (12). Reaction mixtures containing 25 µg
of proteins were incubated at 37°C for 2 h. Luciferase assays
were performed with the luciferase kit obtained from Promega.
Infection and p24 ELISA assay
7 6
pNL4-3. After 2 h, dopamine (100 µM), PMA (10 ng/ml) or
TNF-α (10 ng/ml; Genzyme) was added. Cell culture super-
natants were harvested every 24 h, free virus was removed by
centrifugation. Virus replication in culture was measured by
the production of p24 protein by p24 viral capsid antigen
ELISA (Dupont).
Electrophoretic mobility shift assays (EMSA)
EMSAs were performed with 10 µg of nuclear protein extracts
in a buffer containing 1 ng of 32P 5'-end-labeled κB probe, 1 µg
of poly(dI-dC), 50 ng of sonicated salmon sperm DNA, 10 mM
MgCl2, 25 mM KCl, 1 mM dithiothreitol, 12.5 mM HEPES,
pH 7.8, 10% glycerol, 0.05% Nonidet P-40. Mixtures were
incubated for 15 min at 4°C and protein-bound DNA com-
plexes were analyzed by electrophoresis on a 6% polyacryl-
amide gel in 0.25× TBE (1× TBE = 89 mM Tris, 89 mM boric
acid, 2 mM EDTA). For competition assays, unlabeled κB oligo-
nucleotide was added at a 50-fold molar excess at the same
time as the probe. For supershift assays, antibodies directed
against NF-κBp50 (sc-1190) specific for p50 and p105, or c-Rel
(sc-272) reactive with both c-Rel p75 and NF-κBp65, or NF-AT
(sc-1149) reactive with NF-AT C1, C2, C3 and C4, or Ets1/Ets2
(sc-112) reactive with both Ets1 and Ets2 (Santa Cruz Biotech-
nology), or normal rabbit serum were mixed with nuclear
proteins for 1 h at 4°C prior addition of the probe. The
sequence of the κB synthetic oligonucleotides corresponds to
the –108/–77 sequence of the HIV-1(LAI) LTR.
Western blot analysis
Jurkat cells (107) were harvested and washed in phosphate-
buffered saline (PBS). Following a 10 min incubation at 4°C in
buffer A (10 mMHEPES, pH 7.9, 1.5 mMMgCl2 10 mMKCl,
0.5 mM EDTA, complemented with protease inhibitors),
nuclei were pelleted by centrifugation. Cytoplasmic extracts
were collected and stored at –80°C. Nuclear pellets were
washed with PBS and incubated for 20 min at 4°C in buffer C
(20 mM HEPES, pH 7.9, 25% glycerol, 1.5 mM MgCl2,
420 mM NaCl, 0.2 mM EDTA, 0.5 mM dithiotreitol, comple-
mented with protease inhibitors). Nuclear protein extracts were
collected by a 2 min centrifugation at 10 000 r.p.m. and stored
at –80°C. For western analysis, proteins (10 µg) were subjected to
SDS–PAGE and transferred to nitrocellulose paper. Membranes
were preincubated with 3% bovine serum albumin in PBS
overnight at 4°C and were probed with polyclonal antibodies
described above in EMSA (1:5000 dilution) for 90 min at room
temperature in PBS–0.1% Tween 20 (PBST). After six washes
with PBST for 5 min, membranes were incubated with
peroxidase-labeled anti-rabbit antibody (1:7500 dilution) for
40 min and washed six times for 5 min in PBST. The signal
was visualized by the chemiluminescence protocol (ECL,
Amersham).
RESULTS
Dopamine stimulates HIV-1 transcription and replication
in Jurkat T cells and in PBMC
To investigate the effect of dopamine on HIV-1 gene transcrip-
tion, the LTR-CAT reporter vector containing the full-lengthJurkat cells (10 ) or PBMC (5 × 10 ) were transfected by the
DEAE-dextran method with 5 µg of the proviral genome
LTR of the HIV-1 LAI strain was transfected into Jurkat cells
which were either left untreated or treated for 24 h with
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increasing concentrations of dopamine. Analysis of CAT
activity 48 h after transfection demonstrates that dopamine is
able to stimulate HIV-1 gene transcription in Jurkat cells, in a
dose-dependent manner, up to 3- and 4-fold with 100 and
300 µM dopamine, respectively (Fig. 1).
To study the effect of dopamine on viral replication in the
Jurkat T cell line and in PBMC, cells were transfected with the
proviral clone pNL4-3.Oneday post-transfection, cellswere treated
with 100 µM dopamine or left untreated. HIV-1 replication in the
culture supernatant was monitored every 24 h over a 4-day
period (Fig. 2). Results show that in Jurkat cells, dopamine
treatment led to a 3-fold enhancement of p24 antigen levels, at
each time point, which correlates with the 3-fold increased levels
of HIV-1 transactivation. Interestingly, a 3-fold enhancement
of p24 levels was also detected in PBMC, at time points posterior
to 48 h (Fig. 2).
The NF-κB element is involved in dopamine-induced gene
transcription from the HIV-1 LTR
We have previously shown that in neuronal cells HIV-1 gene
transcription is stimulated in the presence of the transcription
factor COUP-TF and dopamine through the –68/+29 proximal
region of the LTR (12). To delineate the LTR sequences
responsible for dopamine-induced activation in T cells, we
transfected LTR-CAT vectors containing 5' deletions of the
LTR region and tested for their induction following dopamine
treatment (Fig. 3). The dopamine-induced activation was not
affected by deletion of sequences upstream of position –283
(construct 2); deletion of the NF-κB binding sites up to position
–89 (construct 3) dramatically reduced the uninduced expression
and reduced dopamine-induced transcription by half: from 3.1
to 1.5. Further removal of the 3' half of the last NF-κB site and
one Sp1 site up to position –68 (construct 4) or all three Sp1 sites
up to position –40 (construct 5) completely abolished dopamine-
induced transcription. These results indicate that sequences
responsible for dopamine induction of LTR-driven transcription
are contained within nucleotides –283 to –68.
To precisely identify the proximal promoter elements
involved in dopamine responsiveness, we used LTR-CAT
reporter vectors containing internal deletions. Deletion of the
NF-κB and Sp1 sites within the –283/+80 LTR-CAT (con-
struct 6) resulted in a complete lack of dopamine induction,
confirming the importance of these sites in dopamine respon-
siveness. Deletion of the two NF-κB binding sites (construct 7)
Figure 1. Dopamine stimulates HIV-1 LTR-driven transcription in Jurkat T
cells. Cells were transfected with the HIV-1 LTR-CAT reporter vector and
either left untreated or treated for 24 h with different concentrations of
dopamine, as indicated. Cells extractswere prepared 48 h after transfection andCAT
assayswere performed.The fold induction is indicated for each concentration. Error
bars represent standard deviations from three experiments.
Figure 2.Dopamine stimulates HIV-1 replication in Jurkat cells and in PBMC. Cells were transfected with the proviral clone pNL4-3. After 24 h they were treated
with dopamine (100 µM). The production of p24 antigen in the supernatant was evaluated every 24 h. For each time point, p24 was quantitated in triplicate in two
independent experiments. The standard error did not exceed 15%.
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or the three Sp1 sites (construct 8) decreased the induction.
Taken together, these results indicate the essential role of the
NF-κB and the Sp1 elements in dopamine-mediated transcrip-
tional activation of the HIV-1 LTR.
NF-κB sites are sufficient for dopamine-induced gene
transcription
To precisely examine the individual role of NF-κB and Sp1
sites in dopamine responsiveness, we used constructs containing
each of these sites in a heterologous background. In GC-WAP-
CAT and NF-κB-WAP-CAT, the –79/–45 Sp1 sequences or
the –104/–79 sequence containing the two NF-κB sites of the
HIV-1 LTR, respectively, are inserted in front of the whey
acidic protein (WAP) promoter containing a CAAT box and a
TATA box (23). As shown in Figure 4, transcription directed
by the Sp1-containing WAP promoter was not significantly
responsive to dopamine. In contrast, with NF-κB-WAP-CAT,
dopamine treatment led to a 2.7-fold stimulation, comparable
to the 3.1-fold induction observed with HIV-1 LTR. As a control,
the κBmut-WAP-CAT vector, which contains mutations in
both NF-κB binding sites (23), was unable to cause any
dopamine responsiveness. These results demonstrate that NF-κB
sites are sufficient to mediate dopamine-induced gene tran-
scription in Jurkat cells.
Since the NF-κB element is known to mediate phorbol ester
signaling, we measured as a control the induction of transcrip-
tional activity caused by PMA treatment for 24 h. Results show
affected. Interestingly, the transcriptional activity of HIV-1
LTR was stimulated 7.2-fold in the presence of PMA, which is
about double of the 3.1-fold dopamine-induced stimulation
Figure 3. NF-κB sites are necessary for dopamine-induced transcriptional stimulation from the HIV-1 LTR. (Left) LTR-CAT constructs used in transient expression
assays and localization of some binding sites. The NRRE (nuclear receptor responsive element), NF-κB, Sp1 and TATA elements are indicated. The LTR region of
the LAI HIV-1 strain was 5'-end-deleted (constructs 1–5), and the LTR region of HxB2 was internally deleted (constructs 6–9). (Right) Relative CAT activities in
Jurkat cells transfected with the LTR-CAT constructs, either untreated or treated with 100 µM dopamine for 24 h. CAT activities are expressed relative to that of
construct 1 taken as 1. The standard deviation did not exceed 20%. Numbers in brackets indicate the fold stimulation induced by dopamine.
Figure 4. NF-κB sites are sufficient for dopamine-induced gene expression.
The GC-WAP-CAT, κB-WAP-CAT and κBmut-WAP-CAT vectors contain the
–79/–45 three Sp1 sites, the –104/–79 wild-type and mutant NF-κB sequence
from the HIV-1 LTR, respectively, inserted upstream of the promoter of the
WAP and the CAT gene (36). Jurkat cells were transfected with each of these
vectors and were subsequently left untreated or treated for 24 h with either
dopamine (100 µM) or PMA (10 ng/ml). Relative CAT activities are represented.
Error bars represent standard deviations from at least three distinct experiments.that the wild-type κB-WAP promoter was stimulated 68-fold,
while, as expected, the mutant promoter was not significantly (Fig. 5).
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An inhibitor of proteasome is able to abolish dopamine-
induced HIV-1 gene transcription
Activation of NF-κB is induced by pathways which are controlled
by the 26S proteasome complex. The cytoplasmic NF-κB factor,
complexed to the IκB inhibitor, is translocated in the nucleus
following degradation of IκB by the proteasome; in addition,
active NF-κB dimers are generated following processing of
p105 or p100 into p50 and p52 proteins by the proteasome
pathway (24,25). It is known that the inhibitor of proteasome
MG132 prevents nuclear translocation of NF-κB and thus
inhibits NF-κB-mediated LTR-driven transcription (9,26,27).
To further confirm the importance of NF-κB in dopamine
responsiveness, we tested whether the action of dopamine was
repressed in the presence of a proteasome inhibitor. Jurkat cells
were transfected with either HIV-1 LTR-CAT or κB-WAP-CAT
and subsequently treated with 10 µMofMG132 in the absence or
presence of dopamine. Results indicate that treatment with
MG132 alone did not significantly affect LTR-driven tran-
scription (Fig. 5, lanes 1 and 2) and decreased κB-WAP-driven
transcription by half (lanes 7 and 8). As a positive control, the
PMA-induced LTR-driven stimulation could be totally abol-
ished in the presence of 10 µM of MG132 (lanes 3 and 4).
Interestingly, in the presence of dopamine, MG132 treatment
totally suppressed dopamine-induced transcriptional activation
of both LTR-CAT (lanes 5 and 6) and κB-WAP-CAT (lanes 9
and 10). We controlled by EMSA using nuclear extracts of
cells treated by PMA or dopamine that the formation of the
NF-κB complexes was abolished in the presence of MG132
(results not shown). These results clearly show that, similar to
the PMA-induced activity, dopamine-induced transcriptional
activity can be blocked by a proteasome inhibitor, which
strongly suggests that the action of dopamine on the HIV-LTR
or on a heterologous promoter containing κB sites requires the
presence of NF-κB proteins.
Effect of dopamine, PMA and TNF-α on HIV-1 gene
transcription and replication in Jurkat cells and in PBMC
Besides PMA, various cytokines are known to activate HIV-1
gene transcription via NF-κB (25). TNF-α was previously
shown to stimulate LTR-driven CAT activity in Jurkat cells
(4). To examine the effect on HIV-1 gene transcription of the
combined action of two distinct activators of NF-κB, Jurkat
cells and PBMC were transfected with LTR-CAT and LTR-
Luc, respectively, and subsequently treated with either
dopamine, PMA, TNF-α or the combination of two signaling
molecules (Fig. 6A). In Jurkat cells, the combination of PMA
and dopamine, leading each to a 3.1- and 7.2-fold activation,
resulted in an 11.5-fold stimulation, which corresponds to an
additive effect. The most dramatic effect was obtained with the
combined action of dopamine and TNF-α. While dopamine
and TNF-α alone led to a 3.1- and 4.0-fold increase, respec-
tively, the combination of dopamine and TNF-α resulted in a
15-fold synergistic transcriptional stimulation (Fig. 6A, left
panel). In PBMC, the combination of TNF and dopamine,
either in the absence or presence of PMA, led to a 5.8-fold tran-
scriptional increase, which corresponds to an additive effect
(Fig. 6A, right panel).
We also examined the effect of the combination of these
following treatment with combinations of the various stimuli,
dopamine, PMA or TNFα. In Figure 6B are shown the results
obtained 5 days after infection. Interestingly, the combination
of dopamine and PMA (lane 4), as well as dopamine and
TNFα, in the absence (lane 6) or presence of PMA (lane 8) led
to an additive increase in viral replication after 5 days. Since
the PBMCwere preactivated with PHA, it is not surprising that
PMA treatment failed to further increase HIV-1 replication, as
previously described (28).
To examine whether dopamine responsiveness was mediated
through a calcium-dependent and, more specifically, a calcineurin-
dependent pathway, Jurkat cells were transfected with LTR-
CAT and treated for 24 hwith dopamine in the absence or presence
of increasing concentrations of cyclosporine A (0.5–8 µg/ml).
Cyclosporine A was unable to affect the dopamine-induced
transcriptional stimulation, indicating that in Jurkat cells,
dopamine does not enhance the activity of calcineurin (results
not shown).
Dopamine does not change NF-κB DNA binding activities
and NF-κB levels
To examine whether dopamine treatment was able to induce
κB binding activity, we performed EMSA experiments with
nuclear extracts from Jurkat cells treated for various lengths of
time with either dopamine or PMA as a control (Fig. 7A). It
was reported that with Jurkat nuclear extracts, EMSA analysis
displays a complex pattern of binding activity, which can be
affected by the salt concentration in the binding reaction and
the conditions of cell culture (29). Our results show that PMA
Figure 5. The proteasome inhibitor MG132 inhibits dopamine-induced
transcriptional activation driven by the HIV-1 LTR or the κB-WAP promoter.
Jurkat cells were transfected with LTR-CAT or κB-WAP-CAT and either left
untreated or treated for 24 h with dopamine (100 µM) or PMA (10 ng/ml) in
the presence or absence of MG132 (10 µM). CAT assays were performed 48 h
after transfection. The mean values of three independent experiments are
shown. Standard deviations did not exceed 20%.stimuli on the proliferation of HIV-1 in PBMC. HIV-1 replication
in the culture supernatant was monitored over a 5-day period,
treatment caused a large increase of two DNA–protein com-
plexes known to be formed by NF-κB proteins (lanes 1–5). As
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reported previously, NF-κB activity comprises a family of
DNA-binding proteins which, in PMA-stimulated Jurkat cells,
give rise to two discrete DNA–protein complexes (30). In con-
trast with PMA, dopamine treatment did not significantly
affect the minor complex C (lanes 6–10), of electrophoretic
mobility similar to the faster migrating NF-κB complex. The
formation of complex C was specific, since it was competed by
a 50-fold excess of the unlabeled κB oligonucleotide (Fig. 7B,
lanes 1 and 2).
The κB sequence is the binding site of distinct transcription
factors, including members of the NF-κB/Rel family and the
zinc finger proteins MBP1/PRII-BP1/HIV-EP1 and MBP-2
(31). To examine whether complex C was formed by proteins
of the NF-κB family, we performed supershift experiments
with nuclear proteins from cells treated with dopamine for 4 h,
in the presence of polyclonal antibodies directed against either
NF-κBp50, or p65 and c-Rel, or both proteins (Fig. 7B). The
presence of the p50 subunit in complex C was demonstrated,
since addition of anti-p50 antibodies (lanes 4 and 6), but not a
the κB-binding activity (lanes 4 and 6). Since interactions
between Ets and NF-κB/NF-AT proteins have been reported to
regulate the HIV-1 enhancer activity in human T cells (32,33),
we performed supershift experiments with antibodies directed
against NF-AT (C1–C4) and Ets1/Ets2. Both antibodies were
unable to affect complex C formation (results not shown), con-
firming that complex C contains only NF-κBp50, and no Ets or
NF-AT proteins.
Since TNF-α, known to act through NF-κB, led alone and in
combination with dopamine to a 4.0- and 15-fold transcrip-
tional stimulation, respectively, we examined the EMSA pat-
tern obtained with extracts of cells treated with either
dopamine, TNFα or the combination of both signals (Fig. 7C).
As expected, stimulation with TNF-α led to the formation of a
major NF-κB complex (lane 3). Surprisingly, the formation of
this complex was not further increased upon stimulation with
dopamine and TNFα (lane 4). This result confirms that
dopamine does not induce NF-κB DNA binding activities in
Jurkat cells.
Figure 6. Effect of dopamine, PMA and TNFα on HIV-1 gene transcription and replication. (A) Jurkat cells and PBMC were transfected with LTR-CAT and LTR-
Luc, respectively. After 24 h, cells were subsequently treated for 24 h with dopamine (100 µM), PMA (10 ng/ml), TNF-α (10 ng/ml), alone or in combination with
dopamine, as indicated. Relative CAT and luciferase activities are represented. Error bars represent standard deviations from at least three distinct experiments with
Jurkat cells and two experiments with PBMC. (B) Cells were transfected with the proviral clone pNL4-3. After 24 h, they were treated with dopamine (100 µM),
PMA (10 ng/ml), TNF-α (10 ng/ml), alone or in combination as indicated. The production of p24 antigen in the supernatant was evaluated every 24 h for 5 days
in two independent experiments. Only the time point after 5 days is shown.non-immune serum (lane 3) or anti-p65 antibodies (lane 5)
abolished complex C formation and led to the up-shifting of
To further confirm the absence of NF-κB translocation
induced by dopamine, we measured the levels of p50, p65 and
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IκB-α proteins in nuclear and cytoplasmic extracts of Jurkat
cells treated with dopamine over a 2 h period (Fig. 8). Western
blot analysis revealed that p50, p65 and IκB-α proteins were
located mostly in the cytoplasmic fraction, with a low amount
in the nuclear fraction. Interestingly, protein levels were
unchanged in each fraction upon dopamine treatment, over a
2 h period. This result is consistent with and confirms the pre-
vious observations, showing unchanged DNA binding activity
of NF-κB (Fig. 7).
DISCUSSION
Here our studies reveal that the neuromodulator dopamine can
contribute, by itself or in the presence of cytokines or other
NF-κB activating agents, to increase HIV-1 gene expression in
cells of the immune system. In the endocrine system,
dopamine is synthesized by chromaffin cells present in the
adrenal glands, and is secreted into blood vessels following
various stimuli, especially stress conditions (34). Recently,
cells of the immune system, T lymphocytes, were also discovered
to synthesize, transport and bind catecholamines, such as
dopamine (17–20). It was therefore intriguing to test whether
this neuromodulator, whose endocrine-mediated secretion in
the immune sytem is stress dependent, affects HIV-1 gene
expression.
Our experiments reveal that dopamine is able to stimulate
viral replication in the Jurkat T cell line as well as in PBMC,
cytokine TNF-α, leads to a synergistic 15-fold transcriptional
stimulation of the HIV-1 genome in T cells and to an additive
effect in PBMC. TNF-α is known as a potent inducer of HIV-1
transcription and replication (4,35). Elevated levels of various
cytokines, including TNF-α, IL-1, IL-6 and TGF-β, are detected
in the sera of late stage disease of HIV-1-infected patients.
Figure 7. Dopamine does not change NF-κB DNA binding activity in Jurkat cells. (A) EMSA were performed with nuclear protein extracts (5 µg) prepared from
Jurkat cells treated with either PMA (10 ng/ml; lanes 1–5) or dopamine (100 µM; lanes 6–10) for 0, 1, 2, 4 and 8 h. The NF-κB complex, the non-specific
complexes (ns) and the free probe are indicated. (B) Supershift experiments were performed with nuclear proteins isolated from cells treated for 4 h as indicated in
(A) in the presence of antibodies directed against NF-κB p50 or p65 (Santa Cruz Biotechnology) or non-immune serum (NIS) as indicated. A competition experiment was
performed with a 50-fold molar excess of unlabeled κB oligonucleotide (lane 2). Complex C and the supershifted complex SC are indicated. (C) EMSA were
performed with nuclear protein extracts (5 µg) prepared from Jurkat cells treated for 4 h with dopamine (100 µM) and/or TNF-α (10 ng/ml) as indicated.
Figure 8. Dopamine does not change NF-κB levels in Jurkat cells. Western
blot analyses were performed with specific antibodies against p50, p65 and
IκB-α, as indicated. Nuclear and cytoplasmic extracts were prepared from
Jurkat cells treated with dopamine for various times, ranging from 0 to
120 min, as indicated. Specific bands for p50, p65 and IκB-α are indicated by
arrows.which correlates with increased transactivation from the HIV-1
LTR. Moreover, we show that dopamine, in the presence of the These cytokines stimulate viral replication and contribute to
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HIV-1 pathogenesis (reviewed in 26). Our data reveal that the
combination of dopamine and TNF-α is a potent mediator of
increased HIV-1 gene expression.
We further demonstrate that dopamine responsiveness is
mediated through the NF-κB sites of the HIV-1 LTR. A minimal
κB-WAP promoter containing two κB sites, but not a mutated
κBmut-WAP region, was also sufficient for dopamine-
mediated stimulation. Thus, dopamine represents a new member
on the list of stimuli which are κB-mediated transcriptional
activators (25).
The NF-κB/Rel family contains five DNA-binding members,
p50, p52, p65/RelA, c-Rel and RelB (11). Our supershift
results indicate that p50 proteins are present in nuclear extracts
at a low constitutive level, and bind to the κB DNA site.
Surprisingly, in contrast with PMA and TNF-α, dopamine
treatment did not change NF-κB binding activity. These data
establish that dopamine-induced LTR-driven transcription
through the NF-κB sites does not require modification of the
NF-κB DNA binding activity. These observations correlate
with our western blot results, which show that in our culture
conditions, Jurkat cells contain a small nuclear fraction of p50
and p65 NF-κB proteins, which are unaffected by dopamine
treatment. It is well established that NF-κB is retained in the
cytoplasm, through its association with the IκB family of
proteins. Cytosolic IκB-α has a half-life of 1–2 h, and is rapidly
degraded upon stimulation by activating agents such as phorbol
esters, IL-1 and TNF-α (26,36). We show that IκB-α levels are
unaffected by dopamine stimulation, confirming that
dopamine does not induce NF-κB nuclear translocation. Taken
together our findings reveal amechanism for HIV-1 gene activation
by NF-κB, through unchanged DNA binding activities. Similar
results were recently reported in the activation of HIV-1 gene
expression upon TGF-β treatment; HaCaT cells contain a con-
stitutive fraction of NF-κB proteins in the nuclei, unaffected by
TGF-β stimulation (7).
The importance of the proteasome pathway for NF-κB activation
has been well established. NF-κB molecules sequestered in the
cytoplasm by the inhibitor IκB are translocated within the
nuclei following degradation by the proteasome. In addition,
formation of p50 is generated by processing of the N-terminal
portion of p105 by a proteasome-mediated process (11,24,37).
We show here that a proteasome inhibitor which completely
clears the nuclei from all NF-κB molecules, totally abolished
dopamine-induced stimulation. This repression of dopamine
responsiveness by a proteasome inhibitor suggests that the
fraction of NF-κB proteins present in the nuclei is both suff-
icient and essential to mediate dopamine action. It therefore
appears that dopamine, to play its role as a transcriptional
activator, requires the action of another stimulus which first
induces nuclear translocation of NF-κB. Indeed, in HIV-1
infected T cells, autocrine secretion of TNF-α was shown to
control HIV-1 replication because of its ability to maintain
elevated NF-κB in the nucleus (38).
A constitutive NF-κB activity was also described in neurons
(39). Our previous results have shown that in neuronal SK-N-MC
cells, dopamine treatment alone is unable to affect HIV-1 tran-
scription. In these cells, dopamine stimulates transcription in
the presence of increased levels of the nuclear receptor COUP-TF
via the proximal –68/+80 LTR region (12). Similarly, our pre-
CREB proteins via the proximal –68/+80 LTR region. These
data reveal a variety of molecular mechanisms by which
dopamine modulates HIV-1 gene transcription. Here our data
in cells of the immune system stress the fact that dopamine
alone is able to activate HIV-1 gene transcription through NF-κB.
The classic NF-κB activation mechanism, triggered by a
number of extracellular inducers such as phorbol esters, TNF-α
and oxygen peroxide, involves activation of a protein kinase
that phosphorylates IκB and p105, followed by degradation of
IκB, and nuclear translocation of NF-κB (40,41). Recent studies
have demonstrated the existence of a second signaling pathway,
distinct from the IκBα degradation and NF-κB nuclear trans-
location mechanism. Overexpression of p21(CIP1/WAF1) in
Jurkat cells stimulated HIV-1 gene transcription without
inducing changes in NF-κB DNA binding activity (42). TGF-β
was found to activate NF-κB proteins present constitutively in
the nuclei of HaCaT cells, through a yet unidentified pathway
(7). Similarly, a second signaling pathway triggered by IL-1
and TNF-α which confers NF-κB transcriptional competency
was identified in A549 epithelial cells (43). Here our data also
reveal the existence of a dopamine-induced pathway distinct
from the classic NF-κB activation mechanism. Recently, the
transcriptional activity of NF-κB was found to be stimulated
through phosphorylation of p65 by PKA (44). Moreover, phos-
phorylation of p50 was demonstrated to be a key step in the
regulation of NF-κB in adenovirus transformed cells (45).
Such a scenario involving increased phosphorylation of p50
induced by dopamine signaling may explain NF-κB activation
by dopamine, as well as the synergistic effect with TNF-α. Our
data further reveal that the dopamine-mediated effect does not
require signaling through the calcium-activated phosphatase
calcineurin, which activates nuclear import of NF-AT tran-
scription factors (46,47). Clearly, further studies are needed to
elucidate the precise molecular mechanisms underlying NF-κB
activation by dopamine, as well as the dopamine signaling
pathway in T cells. It will also be interesting to examine
whether the action of dopamine is mediated by cellular uptake
or by binding to the cell surface dopamine receptors.
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